A new trading day began on Monday, with Nektar Therapeutics (NASDAQ: NKTR) stock price down -6.61% from the previous day of trading, before settling in for the closing price of $0.88. NKTR’s price has ranged from $0.65 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -2.93%. Meanwhile, its annual earnings per share averaged 50.57%. With a float of $177.79 million, this company’s outstanding shares have now reached $184.46 million.
Let’s determine the extent of company efficiency that accounts for 137 employees. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 70.10%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.57% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Here are Nektar Therapeutics’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.77 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 1.26 million, which is a drop from its year-to-date volume of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 52.61%. Additionally, its Average True Range was 0.09.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 20.24%, which indicates a significant decrease from 21.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.56% in the past 14 days, which was higher than the 80.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8898, while its 200-day Moving Average is $1.1593. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $0.8493. Second resistance stands at $0.8785. The third major resistance level sits at $0.9057. If the price goes on to break the first support level at $0.7929, it is likely to go to the next support level at $0.7657. Now, if the price goes above the second support level, the third support stands at $0.7365.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
With a market capitalization of 151.26 million, the company has a total of 184,458K Shares Outstanding. Currently, annual sales are 90,120 K while annual income is -276,060 K. The company’s previous quarter sales were 24,120 K while its latest quarter income was -37,060 K.
